Navigation Links
Clinical Trials for Lupus Underway After Decades of Drought
Date:10/3/2007

Free Patient Education Campaign Urges Enrollment

LOS ANGELES, Oct. 3 /PRNewswire/ -- For the first time in decades, a significant number of clinical trials are being conducted to seek a treatment, perhaps even a cure, for lupus, a chronic and potentially fatal autoimmune disease that affects more than 1.5 million Americans -- 10,000 in Los Angeles County alone.

A key question that clinical trials answer is, "Will this drug help people and be safe to take?" The question is urgent for people with lupus, because no major new treatments have been approved for the disease in nearly 50 years, and existing medicines are toxic and fraught with side effects.

Until recently, there weren't even trials for people with lupus to enroll in; only recently, with breakthroughs in understanding why the immune system turns against itself in lupus, are new ideas for treatments making their way into the drug approval pipeline.

Fifteen clinical trials in lupus are underway in the Los Angeles area at Cedars-Sinai Medical Center, and an additional 10 are currently recruiting people with lupus. Physicians estimate that 1 in 5 people with the chronic and difficult-to-diagnose illness are not even aware that they are sick with lupus, according to Daniel Wallace, MD, clinical professor of medicine and attending physician in the Division of Rheumatology at Cedars-Sinai. Dr. Wallace is chief investigator at the lupus clinical trial center there.

Lupus Together for Clinical Trials Today, a free patient education program presented by Lupus LA that explains clinical trials for lupus, is scheduled for this Thursday, Oct. 4, from 5:50 to 8 p.m., in the Garden Room at the Veterans Memorial Building, 4117 Overland Ave., Culver City. Registration and a buffet dinner are from 5:30 to 6:30. Pre-registration is required; call Lupus LA at 310-652-7770.

Dr. Wallace and Jennifer Grossman, MD, assistant professor of medicine at UCLA Medical Center, will explain the clinical trial process, why these trials are so important for finding new treatments for lupus, and what is expected of participants. People interested in enrolling will also be given a chance to speak with others who have gone through the process.

"It's important to be informed about the clinical trial process and weigh the pros and cons of participating," Dr. Wallace said. "New therapies that can be identified in clinical trails are critical in the search for a better life for people with lupus. Physicians and scientists are committed to finding these breakthrough treatments. People with lupus are needed, too, as partners in this quest."

Lupus Together for Clinical Trials Today is a campaign of the Lupus Research Institute's National Coalition, a network of regional leaders in lupus. The Institute is the only national nonprofit organization singularly devoted to innovative science in lupus. Its official site for the new clinical trials campaign, http://www.LupusTrials.org, has logged more than 14,000 visitors since it launched in late spring. The campaign is supported in part by unrestricted educational grants from Aspreva Pharmaceuticals and Genentech/Biogen Idec.

About Lupus LA

Lupus LA is dedicated to supporting new science in lupus, and as a National Coalition member partners with the Lupus Research Institute (http://www.LupusResearchInstitute.org) to fund the innovative research needed to prevent, treat, and cure lupus. Lupus LA promotes lupus awareness and education, and is committed to serving the needs of people with lupus and their families in Los Angeles County. Contact Lupus LA at http://www.LupusLA.org, 9220 Sunset Blvd., Suite 200, Loa Angeles, CA. 90069, 310-657-5667.


'/>"/>
SOURCE Lupus LA
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to your ... clip to clip with high quality 4K lens flare footage," said Christina Austin - ... flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... 05, 2016 , ... Edward Buckingham MD , and ... of the newest Sciton laser in January 2017. The Halo is the first ... ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically ...
(Date:12/5/2016)... ... , ... For many years, Andrew G. Zubinas has accumulated over ... of the Lithuanian language and its poetry inspired him in writing “ ... explores all aspects of a living, breathing forest where nothing ever stays the same. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: